What is Sobi?
Founded in 2010, Sobi operates as an international biopharmaceutical company with a specialized focus on rare diseases. The firm maintains a rigorous research and development agenda, primarily targeting advancements in hematology and immunology. By focusing on high-unmet-need therapeutic areas, Sobi has carved out a distinct market position, balancing scientific innovation with commercial scalability. Its operational model is characterized by a deep integration of research, development, and global distribution, ensuring that its specialized therapies reach patients across diverse international markets. The company's strategic focus remains on transforming the lives of individuals with rare conditions through precision medicine and long-term clinical commitment.
How much funding has Sobi raised?
Sobi has raised a total of $152.5M across 2 funding rounds:
Stock Offering
$65.4M
Debt
$87.1M
Stock Issuance/Offering (2011): $65.4M with participation from Bo Jesper Hansen and Investor AB
Debt (2016): $87.1M led by Danske Bank and Svenska Handelsbanken
Key Investors in Sobi
Investor AB
An industrial holding company founded in 1916 that maintains significant shareholdings in multinational corporations and conducts private equity activities globally.
Danske Bank
A prominent Nordic financial institution providing comprehensive banking, mortgage finance, and wealth management services to personal and business clients.
Bo Jesper Hansen
An individual investor and industry veteran providing strategic capital and expertise to support the growth of biopharmaceutical enterprises.
What's next for Sobi?
Looking ahead, Sobi is positioned to leverage its historical capital backing to accelerate its late-stage clinical programs and potential market entries. The firm's strategic roadmap likely involves the continued optimization of its hematology and immunology portfolios, alongside potential inorganic growth opportunities to bolster its pipeline. As the company matures, the focus will shift toward maximizing the commercial impact of its existing therapeutic assets while maintaining the research agility that defined its early growth phase. Investors will be monitoring the firm's ability to maintain its competitive edge in the biopharmaceutical sector, particularly as it navigates the evolving regulatory and healthcare reimbursement environments in Europe and beyond.
See full Sobi company page
